Pancreatic Cell News 7.45 November 15, 2016 | |
| |
TOP STORYTo elucidate the signaling events regulating insulin secretion, the authors applied a recently developed phosphoproteomics workflow. They quantified the time-resolved phosphoproteome of murine pancreatic cells following their exposure to glucose and in combination with small molecule compounds that promote insulin secretion. [Nat Commun] Full Article | |
| |
PUBLICATIONS(Ranked by impact factor of the journal)DIABETES & PANCREATITISControl of Diabetic Hyperglycaemia and Insulin Resistance through TSC22D4 Researchers identified transforming growth factor beta-like stimulated clone (TSC) 22 D4 as a molecular determinant of insulin signaling and glucose handling. [Nat Commun] Full Article Neurotrophin Signaling Is Required for Glucose-Induced Insulin Secretion Scientists uncovered a regulatory mechanism by which glucose recruits vascular-derived neurotrophins to control insulin secretion. [Dev Cell] Abstract | Press Release | Graphical Abstract Novel Method to Rescue a Lethal Phenotype through Integration of Target Gene onto the X-Chromosome Scientists present a novel method to efficiently integrate a target gene on the X chromosome, resulting in a mosaic pattern of the target protein expression. The resulting Spink3−/−;XXSPINK1 mice developed spontaneous pancreatitis, representing a novel genetic model for this disease. [Sci Rep] Full Article Exendin-4 Promotes Pancreatic β-Cell Proliferation via Inhibiting the Expression of Wnt5a It has been reported that exendin-4 promoted pancreatic β cell proliferation by regulating the expression level of Wnt4. Scientists investigated whether other Wnt isoforms take part in accommodation of β-cell proliferation. [Endocrine] Abstract PANCREATIC CANCERInvestigators confirmed that incubation in tumor-associated macrophage-conditioned medium reduces the gemcitabine-induced apoptosis of pancreatic ductal adenocarcinoma cells. [Cancer Lett] Abstract Naringenin, one of the most abundant flavonoids in natural citrus fruits, has been investigated for its ability to inhibit growth of breast, colon, gastric and prostate cancer cells. However, naringenin-induced cell death in pancreatic cancer is not well understood. Researchers analyzed the naringenin-induced apoptosis mechanism using human pancreatic cancer SNU-213 cells. [Food Chem Toxicol] Abstract The authors characterized the expression and functionality of RhoGDI3 and its target GTPases, RhoG and RhoB in pancreatic cell lines from both normal pancreatic tissue and tissue in late stages of pancreatic ductal adenocarcinoma, and compared them to human biopsies. [PLoS One] Full Article Researchers clarified the microRNA signature of pancreatic stellate cells-derived exosomes and their effects on pancreatic cancer cells. [Pancreas] Abstract | |
| |
REVIEWSClinical Pancreatic Islet Transplantation The authors outline the techniques required for human islet isolation, in vitro culture before the transplant and clinical islet transplantation, and discuss indications, optimization of recipient immunosuppression and management of adjunctive immunomodulatory and anti-inflammatory strategies. [Nat Rev Endocrinol] Abstract Pancreas β-cell Regeneration: Facultative or Dedicated Progenitors? Scientists focus on regenerative events in the pancreas with emphasis on the restoration of β-cell mass. They present an overview of regenerative responses noted within the different pancreatic lineages, following injury. [Mol Cell Endocrinol] Abstract Visit our reviews page to see a complete list of reviews in the pancreatic cell research field. | |
| |
SCIENCE NEWSADI-PEG 20 Radio-Sensitizes Pancreatic Cancer Cells by Amplifying Early Endoplasmic Reticulum Stress Polaris Group announced that ADI-PEG 20, arginine deiminase formulated with polyethylene glycol, can selectively enhance the effect of radiation in argininosuccinate synthetase deficient pancreatic tumors according to results presented by researchers from MD Anderson Cancer Center. [Press release from Polaris Group discussing research presented at the 2016 Annual Meeting of the American Society for Radiation Oncology (ASTRO), Boston] Press Release Provectus Biopharmaceuticals Announces Poster Presentation on Pv-10 Provectus Biopharmaceuticals, Inc. announced the presentation of data that shows that PV-10 has therapeutic activity in murine models of pancreatic cancer, and that this is augmented when intralesional PV-10 is combined with systemic gemcitabine, a standard chemotherapeutic agent used to treat this disease. [Press release from Provectus Biopharmaceuticals, Inc. discussing research presented at the Society for Immunotherapy of Cancer (SITC) 2016 Annual Meeting, National Harbor] Press Release Fractyl Presents New Revita DMR Liver Data in Type 2 Diabetes Investigators reported data on a subcohort of patients with type 2 diabetes in the first-in-human study of Revita duodenal mucosal resurfacing (DMR), showing improvements in markers of insulin resistance, systemic inflammation and oxidative stress post-procedure, suggesting that Revita DMR may be a method for correction of hyperglycemia and key pathophysiological drivers of fatty liver disease. [2016 Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), Boston] Press Release | |
| |
INDUSTRY NEWSCell Culture Company (C3) Deal Targets Pancreatic Cancer Cell Culture Company (C3) announced it has entered into an agreement with a China-based joint venture to produce a clinical-grade antibody-based therapeutic vaccine targeting pancreatic cancer. [Cell Culture Company (Business Wire, Inc.)] Press Release Halozyme Therapeutics, Inc. announced an agreement to collaborate on clinical studies evaluating up to eight different tumor types beginning in 2017. This study will have an initial focus on gastrointestinal malignancies, including pancreatic and gastric cancers. [Halozyme Therapeutics, Inc.] Press Release Researchers Launch First Clinical Trial for Wolfram Syndrome Researchers at Washington University School of Medicine in St. Louis are launching a new clinical trial to assess the safety of a drug treatment for patients with the rare disease Wolfram syndrome. Wolfram syndrome affects about one in every 500,000 people worldwide. Many of those patients die prematurely from the disease. Patients with Wolfram syndrome typically develop diabetes at a very young age and require insulin injections several times each day. [Washington University School of Medicine] Press Release Boston Biomedical Announces Orphan Drug Designation for Napabucasin in Pancreatic Cancer Boston Biomedical announced that its lead investigational compound, napabucasin, has received Orphan Drug Designation from the U.S. Food and Drug Administration in the treatment of pancreatic cancer. [Boston Biomedical] Press Release ARMO BioSciences, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted the company’s lead investigational immuno-oncology drug AM0010 (PEGylated Interleukin-10) Orphan Drug designation for the treatment of pancreatic cancer. [ARMO BioSciences, Inc.] Press Release MabVax Therapeutics Holdings, Inc. reported on progress from its two HuMab-5B1 antibody Phase I programs evaluating the use of MVT-5873 as a therapeutic antibody and MVT-2163 as an immuno-PET imaging agent in patients with locally advanced and metastatic pancreatic cancer or other CA19-9 positive malignancies. [MabVax Therapeutics Holdings, Inc.] Press Release Elcelyx Therapeutics announced that its Phase IIb dose ranging study met the primary endpoint of showing a statistically significant reduction in HbA1c at 16 weeks with Metformin Delayed Release compared with placebo in subjects with type 2 diabetes. [Elcelyx Therapeutics, Inc.] Press Release | |
| |
POLICY NEWSSeeding Doubt: How Self-Appointed Guardians of “Sound Science” Tip the Scales Toward Industry At a time when public mistrust of science runs high, and non-experts are hard-pressed to separate fact from industry-sponsored spin, Sense About Science, a charity based in London with an affiliate in New York, presents itself as a trustworthy arbiter. [The Intercept] Editorial Rwanda Feels the Pinch as Donors Slash Health Aid Rwanda has made major public-health strides since the country’s genocide against the Tutsi people ended in June 1994, but declines in foreign aid now threaten that progress. Donors such as the US President’s Emergency Plan for AIDS Relief and the Global Fund to Fight AIDS, Tuberculosis and Malaria have reduced assistance to Rwanda by 40% over the past three years, jeopardizing advances in a country seen as a development success story. [Nature News] Editorial CRISPR Gene-editing Tested in a Person for the First Time A Chinese group has become the first to inject a person with cells that contain genes edited using the revolutionary CRISPR–Cas9 technique. A team led by oncologist Lu You at Sichuan University in Chengdu delivered the modified cells into a patient with aggressive lung cancer as part of a clinical trial at the West China Hospital, also in Chengdu. The move by Chinese scientists could spark a biomedical duel between China and the United States. [Nature News] Editorial Experiment to Raise the Dead Blocked in India The Indian Council of Medical Research (ICMR) has derailed a controversial experiment that would seek to revive brain-dead accident victims. ICMR’s National Institute of Medical Statistics removed the “ReAnima” trial from India’s clinical trial registry. [Science Insider] Editorial
| |
EVENTSNEW 19th International Conference on Clinical Application of Adult Stem Cells Visit our events page to see a complete list of events in the community.
| |
JOB OPPORTUNITIESNEW Assistant Professor – Cancer Cell Biology (North Dakota State University) Research Fellow – Genome Regulation and Diabetes (Imperial College London) Postdoctoral Training Fellow – Immunoncology (Institute of Cancer Research) Postdoctoral Scholar – Diabetes Research (University of Oklahoma Health Science Center) Postdoctoral Researcher – Type II Diabetes and Islet Biology (Lund University) Research Associate – Cancer Therapeutics (Cancer Research UK Cambridge Institute) Postdoctoral Fellow – Cancer and Immunometabolism (The University of Michigan) Postdoctoral Researcher – Pancreatic Cancer (Van Andel Research Institute) Postdoctoral Position – Immunology of Diabetes (INSERM) Vice President – Pancreatic Cancer Disease Lead (Celgene Corporation) Postdoctoral Research Fellow – Pancreas Cancer (Fred Hutchinson Cancer Research Center) Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
| |
Have we missed an important article or publication in Pancreatic Cell News? Click here to submit! Comments or suggestions? Submit your feedback here. | |
|
Home Pancreatic Cell News Volume 7.45 | Nov 15 2016